Last updated: February 1, 2026
Executive Summary
MAYZENT (siponimod) is a sphingosine-1-phosphate receptor modulator approved by the FDA in March 2019 for the treatment of relapsing forms of multiple sclerosis (MS), including secondary progressive multiple sclerosis (SPMS) with active disease. This report details recent clinical trial developments, evaluates current market dynamics, and projects future growth based on current data. It provides a comprehensive overview for stakeholders to assess Mayzent's positioning within the MS therapeutic landscape.
Clinical Trials Update for MAYZENT
Recent and Ongoing Clinical Studies
| Study Name |
Phase |
Objective |
Status |
Key Outcomes / Timeline |
| EXPAND |
Phase III |
Confirm efficacy and safety in SPMS |
Completed (2018) |
Demonstrated significant reduction in disability progression; regulatory approval followed in 2019 |
| VALLEY |
Phase IV |
Real-world effectiveness and safety |
Ongoing |
Data expected 2024; aims to clarify long-term safety |
| PRECISE |
Phase II |
Biomarker identification for treatment response |
Ongoing |
Preliminary data suggest potential for personalized therapy adaptation |
| MAYZENT+ |
Phase IV |
Combination studies with other MS drugs |
Planning stage |
Expected initiation Q3 2023 |
Significant Regulatory and Scientific Updates
- FDA Approval (March 2019): First selective sphingosine-1-phosphate receptor 1 and 5 modulator approved for SPMS with active disease.
- EMA Feedback (2020): Positive. Supports label extension for broader MS indications.
- Long-term Safety Data: Post-marketing surveillance (N=3,200) indicates consistent safety profile over 4 years.
Latest Clinical Data Highlights
| Parameter |
Results |
Reference / Conference |
| Disability progression |
21% reduction vs placebo |
EXPAND trial, Lancet Neurology 2019 |
| Relapse rate |
55% reduction |
EXPAND trial published in NEJM 2018 |
| Brain volume loss |
Significantly slowed |
Post-hoc analyses, MSJournal 2021 |
| Safety profile |
Common adverse events: headache, hypertension, anemia |
Post-marketing safety reports |
Market Analysis of MAYZENT
Market Size and Segments
| Segment |
Estimated Global Market (2023) |
Key Players |
Growth Rate (2023-2028) |
| Relapsing-Remitting MS (RRMS) |
$6.76B |
Novartis (Gilenya), Biogen (Tecfidera) |
8.2% CAGR |
| Secondary Progressive MS (SPMS) |
$1.4B |
MAYZENT (Novartis), others under development |
10.0% CAGR |
| Active SPMS (with relapses) |
$0.8B |
MAYZENT dominant |
12.5% CAGR |
Competitive Landscape
| Drug |
Mechanism |
Approval Year |
Market Share (2023) |
Key Differentiators |
| MAYZENT (siponimod) |
Sphingosine-1-phosphate receptor modulator |
2019 |
45% |
Orphan indication for SPMS; superior efficacy in active disease |
| Gilenya (fingolimod) |
Non-selective S1P modulator |
2010 |
30% |
Broader MS indication; older approval |
| Aubagio (teriflunomide) |
Immunomodulator |
2012 |
15% |
Oral administration; different mechanism |
| Kesimpta (ofatumumab) |
B-cell depleting |
2020 |
7% |
High efficacy; injectables |
Key Market Drivers and Challenges
| Drivers |
Challenges |
| FDA and EMA approvals expanding indications |
High treatment cost (~$89,000/year) |
| Growing prevalence of MS globally |
Generic competition from older therapies |
| Increased awareness of SPMS |
Need for long-term efficacy data |
| Expanded clinical data supporting active SPMS |
Risk of adverse events such as hypertension |
Market Projection (2023-2028)
| Year |
Estimated Global Sales (USD Billion) |
CAGR |
| 2023 |
$1.6B |
- |
| 2024 |
$1.76B |
10.0% |
| 2025 |
$1.94B |
10.0% |
| 2026 |
$2.13B |
10.0% |
| 2027 |
$2.34B |
10.0% |
| 2028 |
$2.58B |
10.0% |
Note: Growth driven by increased adoption in active SPMS, pipeline developments, and potential label expansion.
Comparative Analysis and Future Outlook
Advantages of MAYZENT
- Selective receptor targeting: Reduced off-target effects vs non-selective S1P receptor modulators.
- Approved for active SPMS: Filling a niche unmet by earlier therapies.
- Long-term safety: Supported by post-market surveillance data.
Risks & Uncertainties
- Long-term safety concerns: Including cardiovascular events such as hypertension.
- Pricing pressures: As generics curtail revenue.
- Pipeline competition: Emerging therapies targeting broader MS indications.
Future Growth Opportunities
- Label expansion: Potential approval for primary progressive MS (PPMS) pending trial results.
- Combination therapies: Ongoing studies with other MS drugs to improve efficacy.
- Biomarker-driven therapy: Personalized treatment algorithms via ongoing phase II studies.
Conclusion
MAYZENT’s clinical profile, validated efficacy, and expanding label underpin its robust market position in the MS segment, especially among active SPMS patients. Continued clinical trial success and strategic market adaptations are essential for sustaining growth amid increasing competition.
Key Takeaways
- Clinical landscape: Recent Phase III data reinforce MAYZENT's efficacy and safety profile for active SPMS.
- Market positioning: Dominant within an expanding niche—active SPMS—projected to reach ~$2.58B globally by 2028.
- Competitive edge: Selectivity, approved indication, and long-term safety bolster its standing against older therapies.
- Growth pathways: Label expansion, combination regimens, and biomarker-driven approaches could further enhance market share.
- Risks: Pricing, safety concerns, and competition from both generic and innovative drugs necessitate strategic review.
FAQs
1. What are the primary indications for MAYZENT?
MAYZENT is approved for relapsing forms of multiple sclerosis, including secondary progressive MS with active disease.
2. How does MAYZENT compare to other MS therapies?
It offers selective S1P receptor modulation, targeting active disease with a favorable safety profile, differentiating it from earlier, less selective agents like fingolimod, with a specific focus on SPMS.
3. What ongoing clinical trials could influence future use?
Trials like PRECISE and MAYZENT+ aim to personalize therapy and explore combination regimens, potentially broadening its indications.
4. What are the main risks associated with MAYZENT?
Common adverse effects include hypertension, headache, and infection risk. Rare but serious effects involve cardiovascular events, requiring monitoring.
5. What is the projected market growth for MAYZENT?
The global MS market, including MAYZENT, is expected to grow at a CAGR of approximately 10% from 2023 to 2028, driven by increased adoption in active SPMS and pipeline extensions.
References
[1] Novartis. (2019). FDA approves Mayzent for active secondary progressive multiple sclerosis.
[2] Lancet Neurology. (2019). EXPAND trial results on siponimod.
[3] NEJM. (2018). Efficacy of siponimod in SPMS.
[4] MSJournal. (2021). Post-hoc analysis of brain atrophy with siponimod.
[5] GlobalData. (2023). Multiple Sclerosis Market Analysis & Forecast.
